Analyst firm issues research notes on EyePoint Pharmaceuticals, which is listed on the Nasdaq stock exchange.
3 reports, 1 independent
Updated Aug 18
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst firm issues research notes on EyePoint Pharmaceuticals, which is listed on the Nasdaq stock exchange.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Cantor Fitzgerald provided ratings and price targets for EyePoint Pharmaceuticals.1 source
EyePoint Pharmaceuticals is listed on Nasdaq and is currently receiving analyst research reports.1 source
Keep exploring
The entities involved
-
EyePoint Pharmaceuticals (United Kingdom)
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
Related events
- VSE Corporation was listed on the Nasdaq stock exchange and received analyst coverage and price targets from Morgan Stanley and TipRanks.
- BioPharma stock was traded on the NASDAQ stock exchange on July 30, 2026, with its performance tracked by financial blogs.
- Shares of Syndax Pharmaceuticals were traded on the Nasdaq stock exchange on August 12, 2026.
- Materialise listed its shares on the Nasdaq stock exchange on August 27, 2026.
- BOK Financial Corporation stock is publicly traded on the NASDAQ exchange.